Adalimumab for the treatment of behçet's disease: Experience in 19 patients

Rheumatology (United Kingdom)

Volumn 51, Issue 10, 2012, Pages 1825-1831

  Perra, Daniela ^a   Alba, Marco A ^a   Callejas, José Luis ^b   Mesquida, Marina ^a   Ríos Fernández, Raquel ^b   Adán, Alfredo ^a   Ortego, Norberto ^b   Cervera, Ricard ^a   Espinosa, Gerard ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Adalimumab; Beh et's disease; Refractory; Treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; COLCHICINE; CYCLOSPORIN A; CYCLOSPORIN C; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PARACETAMOL; PREDNISONE; THALIDOMIDE;

ADULT; ANGIONEUROTIC EDEMA; APHTHOUS STOMATITIS; ARTICLE; BEHCET DISEASE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLICULITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; PRIORITY JOURNAL; RETINA VASCULITIS; RETROSPECTIVE STUDY; SPAIN; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; URTICARIA; UVEITIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BEHCET SYNDROME; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84867119008     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes130     Document Type: Article

References (45)

1. Yurdakul S, Hamuryudan V, Yazici H. Behcet syndrome. Curr Opin Rheumatol 2004;16:38-42.
2. Hatemi G, Silman A, Bang D et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008;67:1656-62.
3. Hatemi G, Silman A, Bang D et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 2009;68:1528-34.
4. Sfikakis PP, Markomichelakis N, Alpsoy E et al. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology 2007;46: 736-41.
5. Bae JH, Lee SC. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease. Retina 2011, Oct 18 [Epub ahead of print].
6. Davatchi F, Shahram F, Chams H et al. High dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results. Adv Exp Med Biol 2003; 528:579-84.
7. Iwata S, Saito K, Yamaoka K et al. Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behcet's disease. Mod Rheumatol 2011;21:184-91.
8. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49:725-8.
9. Ward EM, Woodward TA, Mazlumzadeh M, Calamia KT. Gastrointestinal disease in Behcet's disease. Adv Exp Med Biol 2003;528:459-64.
10. Alpsoy E, Durusoy C, Yilmaz E et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71.
11. Hamuryudan V, Moral F, Yurdakul S et al. Systemic interferon alpha 2b treatment in Behcet's syndrome. J Rheumatol 1994;21:1098-100.
12. Mochizuki M. Immunotherapy for Behcet's disease. Int Rev Immunol 1997;14:49-66.
13. Nichols JC, Ince A, Akduman L, Mann ES. Interferon-alpha 2a treatment of neuro-Behcet disease. J Neuroophthalmol 2001;21:109-11.
14. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G. Interferon alpha for ocular Behcet's disease. Acta Ophthalmol Scand 1997;75:720-2.
15. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998;134:1010-6.
16. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990;335: 1078-80.
17. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-35.
18. Kotter I, Vonthein R, Zierhut M et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004;33: 311-9.
19. Deuter CM, Kotter I, Gunaydin I, Zierhut M, Stubiger N. [Ocular involvement in Behcet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a]. Ophthalmologe 2004;101:129-34.
20. Kotter I, Zierhut M, Eckstein AK et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-31.
21. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediators Inflamm 2002;11:87-93.
22. Turan B, Gallati H, Erdi H et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechcet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24:128-32.
23. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41: 61-70.
24. Newswire J. Siyaku announces anti TNF-a monoclonal antibody preparation REMICADE(R) for drip infusion 100 receives approval as additional indication of treating Behcet's disease with refractory uveoretinitis 2007. http:// www.japancorp.net/press-release/14059/tanabe-siyakuannounces-anti-tnf-a-monoclonal-antibody-preparationremicade% 28r%29-for-drip-infusion-100-receivesapproval-as-additional-indication-of-treTanabe (30 April 2012, date last accessed).
25. Atzeni F, Leccese P, D'Angelo S, Sarzi-Puttini P, Olivieri I. Successful treatment of leg ulcers in Behcet's disease using adalimumab plus methotrexate after the failure of infliximab. Clin Exp Rheumatol 2010;28(4 SUPPL. 60):S94.
26. Belzunegui J, Lopez L, Paniagua I, Intxausti JJ, Maiz O. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behcet's disease. Clin Exp Rheumatol 2008;26(4 SUPPL. 50):S133-4.
27. Leccese P, D'Angelo S, Angela P, Coniglio G, Olivieri I. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab. Clin Exp Rheumatol 2010;28(4 SUPPL. 60):S102.
28. Lee SW, Lee SY, Kim KN, Jung JK, Chung WT. Adalimumab treatment for life threatening pulmonary artery aneurysm in Behcet disease: a case report. Clin Rheumatol 2010;29:91-3.
29. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye 2007;21:824-5.
30. Takase K, Ohno S, Ideguchi H et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int 2011;31: 243-5.
31. van Laar JA, Missotten T, van Daele PL et al. Adalimumab: a new modality for Behcet's disease? Ann Rheum Dis 2007;66:565-6.
32. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
33. Adan A, Hernandez V, Ortiz S et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behcet's disease after withdrawal of infusions. Int Ophthalmol 2010; 30:577-81.
34. Callejas-Rubio JL, Sanchez-Cano D, Rios-Fernandez R, Ortego-Centeno N. [Treatment of Behcet's disease with adalimumab]. Med Clin 2008;131:438-9.
35. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm 2010;18:226-32.
36. Lee RW, Dick AD. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behcet's uveitis. Br J Ophthalmol 2010;94:269-70.
37. Aikawa NE, Goncalves C, Silva CA, Bonfa E, de Carvalho JF. Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Behcet's disease. Rheumatol Int 2011;31:1097-9.
38. Iwata S, Saito K, Yamaoka K et al. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Rheumatology 2009;48:1012-3.
39. Kram MT, May LD, Goodman S, Molinas S. Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003;46:118-21.
40. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 2001;120:995-9.
41. De Cassan C, De Vroey B, Dussault C et al. Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease. J Crohns Colitis 2011;5:364-8.
42. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41:61-70.
43. Olivieri I, Leccese P, D'Angelo S et al. Efficacy of adalimumab in patients with Behcet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 2011;29(4 Suppl. 67):S54-7.
44. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;CD008794.
45. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180-210.